PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study

Journal of Heart and Lung Transplantation

Volumn 36, Issue 1, 2017, Pages 1-12

  Maltais, Simon ^a   Kilic, Ahmet ^b   Nathan, Sriram ^c   Keebler, Mary ^d   Emani, Sitaramesh ^b   Ransom, John ^e   Katz, Jason N ^f   Sheridan, Brett ^g   Brieke, Andreas ^h   Egnaczyk, Gregory ⁱ   Entwistle, John W ^j   Adamson, Robert ^k   Stulak, John ^a   Uriel, Nir ^l   O'Connell, John B ^m   Farrar, David J ^m   Sundareswaran, Kartik S ^m   Gregoric, Igor ^c  

^a MAYO CLINIC   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c EAST TEXAS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e Baptist Health Arkansas   (United States)

^f Division of Cardiology   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ CHRIST HOSPITAL   (United States)

^j THOMAS JEFFERSON UNIVERSITY   (United States)

^k SHARP MEMORIAL HOSPITAL   (United States)

^l UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^m St Jude Medical Inc   (United States)

more..

Author keywords

best practices; continuous flow left ventricular assist device (CF LVAD); HeartMate II; prevention; pump thrombosis

Indexed keywords

GROWTH HORMONE; HEPARIN; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; FEMALE; FOLLOW UP; HEART FAILURE; HEMOLYSIS; HUMAN; HYDROTHORAX; LACTATE DEHYDROGENASE BLOOD LEVEL; LEFT VENTRICULAR ASSIST DEVICE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTHESIS IMPLANTATION; PROSTHESIS THROMBOSIS; PROTOCOL COMPLIANCE; RISK MANAGEMENT; SURGICAL TECHNIQUE; ADVERSE DEVICE EFFECT; CLINICAL TRIAL; DISEASE MANAGEMENT; HEART ASSIST DEVICE; INCIDENCE; MORTALITY; POSTOPERATIVE COMPLICATION; PROCEDURES; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; SECONDARY PREVENTION; SURVIVAL RATE; THROMBOSIS; TOTAL QUALITY MANAGEMENT; TRENDS; UNITED STATES;

DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; QUALITY IMPROVEMENT; REGISTRIES; RISK FACTORS; SECONDARY PREVENTION; SURVIVAL RATE; THROMBOSIS; UNITED STATES;

EID: 85007012266     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2016.10.001     Document Type: Article

References (34)

1. 1 Starling, R.C., Naka, Y., Boyle, A.J., et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 57 (2011), 1890–1898.
2. 2 Stulak, J.M., Davis, M.E., Haglund, N., et al. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg 151 (2016), 177–189.
3. 3 Starling, R.C., Moazami, N., Silvestry, S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370 (2014), 33–40.
4. 4 Kirklin, J.K., Naftel, D.C., Kormos, R.L., et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 33 (2014), 12–22.
5. 5 Stulak, J.M., Sharma, S., Maltais, S., Management of pump thrombosis in patients with left ventricular assist devices. Am J Cardiovasc Drugs 15 (2015), 89–94.
6. 6 Stulak, J.M., Maltais, S., A different perspective on thrombosis and the HeartMate II. N Engl J Med 370 (2014), 1467–1468.
7. 7 Najjar, S.S., Slaughter, M.S., Pagani, F.D., et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 33 (2014), 23–34.
8. 8 Crow, S., John, R., Boyle, A., et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 137 (2009), 208–215.
9. 9 Uriel, N., Pak, S.W., Jorde, U.P., et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 56 (2010), 1207–1213.
10. 10 Cowger, J., Pagani, F.D., Haft, J.W., Romano, M.A., Aaronson, K.D., Kolias, T.J., The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail 3 (2010), 668–674.
11. 11 Taghavi, S., Ward, C., Jayarajan, S.N., Gaughan, J., Wilson, L.M., Mangi, A.A., Surgical technique influences HeartMate II left ventricular assist device thrombosis. Ann Thorac Surg 96 (2013), 1259–1265.
12. 12 Uriel, N., Han, J., Morrison, K.A., et al. Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant 33 (2014), 51–59.
13. 13 Adamson, R.M., Bower, B.L., Sundareswaran, K.S., Farrar, D.J., Dembitsky, W.P., Radiologic assessment of HeartMate II position: minimal pump migration after long-term support. J Heart Lung Transplant 34 (2015), 1617–1623.
14. 14 Adamson, R.M., Mangi, A.A., Kormos, R.L., Farrar, D.J., Dembitsky, W.P., Principles of HeartMate II implantation to avoid pump malposition and migration. J Card Surg 30 (2015), 296–299.
15. 15 Klodell, C.T., Massey, H.T., Adamson, R.M., et al. Factors related to pump thrombosis with the Heartmate II left ventricular assist device. J Card Surg 30 (2015), 775–780.
16. 16 Heatley, G., Sood, P., Goldstein, D., et al. Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. J Heart Lung Transplant 35 (2016), 528–536.
17. 17 Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 34 (2015), 1495–1504.
18. 18 Jorde, U.P., Kushwaha, S.S., Tatooles, A.J., et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 63 (2014), 1751–1757.
19. 19 Boyle, A.J., Jorde, U.P., Sun, B., et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol 63 (2014), 880–888.
20. 20 Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS Registry. J Heart Lung Transplant 34 (2015), 1515–1526.
21. 21 Yang, F., Kormos, R.L., Antaki, J.F., High-speed visualization of disturbed pathlines in axial flow ventricular assist device under pulsatile conditions. J Thorac Cardiovasc Surg 150 (2015), 938–944.
22. 22 Klodell CT, Massey HT, Adamson R, et al. Factors related to pump thrombosis at select medium to high volume centers. Paper presented at: 34th Annual Meeting and Scientific Sessions, International Society of Heart and Lung Transplantation. April 10–13, 2014; San Diego, CA.
23. 23 Hoefer, D., Velik-Salchner, C., Antretter, H., Increase in left ventricular assist device thrombosis. N Engl J Med, 370, 2014, 1464.
24. 24 Schmitto, J.D., Avsar, M., Haverich, A., Increase in left ventricular assist device thrombosis. N Engl J Med 370 (2014), 1463–1464.
25. 25 Al-Quthami, A.H., Jumean, M., Kociol, R., et al. Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis. Circ Heart Fail 5 (2012), e68–e70.
26. 26 Bashir, J., Cheung, A., Kaan, A., Kearns, M., Ibey, A., Ignaszewski, A., Thrombosis and failure of a HeartMate II device in the absence of alarms. J Heart Lung Transplant 30 (2011), 1197–1199.
27. 27 Ravichandran, A.K., Parker, J., Novak, E., et al. Hemolysis in left ventricular assist device: a retrospective analysis of outcomes. J Heart Lung Transplant 33 (2014), 44–50.
28. 28 Stulak, J.M., Lee, D., Haft, J.W., et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 33 (2014), 60–64.
29. 29 Mehra, M.R., Stewart, G.C., Uber, P.A., The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant 33 (2014), 1–11.
30. 30 Kirkin, J.K., Naftel, D.C., Kormos, R.L., et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 33 (2014), 12–22.
31. 31 Salerno, C.T., Sundareswaran, K.S., Schleeter, T.P., Moanie, S.L., Farrar, D.J., Walsh, M.N., Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events. J Heart Lung Transplant 33 (2014), 809–815.
32. 32 Kamouh, A., John, R., Eckman, P., Successful treatment of early thrombosis of HeartWare left ventricular assist device with intraventricular thrombolytics. Ann Thorac Surg 94 (2012), 281–283.
33. 33 Schlendorf, K., Patel, C.B., Gehrig, T., et al. Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. J Card Fail 20 (2014), 91–97.
34. 34 Stulak, J.M., Dunlay, S.M., Sharma, S., et al. Treatment of device thrombus in the HeartWare HVAD: success and outcomes depend significantly on the initial treatment strategy. J Heart Lung Transplant 34 (2015), 1535–1541.